AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
MELBOURNE, Australia, and MENLO PARK, Calif., April 4 /PRNewswire- FirstCall/ -- ChemGenex Pharmaceuticals Limited announced today the presentation of three posters describing aspects of its pre-clinical research at the American Association of Cancer Research 97th Annual Meeting in Washington DC.
Posters describing preclinical research findings were presented on Ceflatonin(R), Quinamed(R) and ChemGenex's earlier-stage anti-cancer compound CXS299 by research teams from ChemGenex and leading academic institutions.
Highlights of the posters include:
1. The discovery that Ceflatonin, which is currently in phase 2 clinical
trials for use in various leukemia indications, can suppress the
development of blood vessels, a process known as angiogenesis. The
development of angiogenic inhibitors has been an important focus in
the search for novel cancer therapeutics. The poster examines the
efficacy of Ceflatonin when used alone or in combination with some
topoisomerase inhibitors, and reports some significant anticancer
responses that may be of value in controlling solid tumor growth.
(Abstract 564).
2. Observations that Quinamed, which is currently in Phase 2 clinical
trials for use in various solid tumors, has synergistic effects when
used with some anti-leukemic agents. Using a cell culture model of
acute myeloid leukemia (AML), it was shown that Quinamed combined with
mitoxantrone resulted in more than additive anticancer responses.
This result suggests possible future combination therapies for a range
of leukemias. (Abstract 2140).
3. The discovery by a team at the M.D. Anderson Cancer Center in Houston,
Texas that CXS299 causes cell death when used to treat breast and
prostate cancer cell lines which are resistant to cisplatin, a widely
used anti-cancer agent. CXS299 maintains the ability to activate the
tumor suppressor protein p53 in resistant cells, an ability that
existing therapeutics lack. This discovery confirms that CXS299 has
significant potential as a therapeutic agent for patients who have
inherent resistance, or who develop resistance to cisplatin. (Abstract
5420).
About ChemGenex Pharmaceuticals Limited (http://www.chemgenex.com/ )
ChemGenex Pharmaceuticals is a pharmaceutical development company dedicated to improving the lives of patients by developing therapeutics in the areas of oncology, diabetes, obesity, and depression. ChemGenex harnesses the power of genomics for target discovery and ...